Comparison of TNF- by Mahshid Vafajoo (21144147)

Detection of ETs using SYTOX green. by Mahshid Vafajoo (21144147)

DataSheet1_Glucose-lowering medications and glucose levels as the major determinants of progression of carotid atherosclerosis in middle-aged adults and elders: a community-based p... by Chao-Liang Chou (2854052)

“…</p>Conclusion<p>We found that more than 50% of CA-positive subjects had CAP in 4 years and higher FPG significantly increased and GLM significantly decreased the risks of CAP. …”

<i>Kif15</i> deficiency affects the expression of excitatory postsynaptic receptors in PFC and hippocampus. by Xiaomei He (795333)

“…<b>(G and J)</b>: The expression of PSD95 in hippocampus of <i><i>Kif15</i></i>^<i>-/-</i> mice decreased at 3 weeks, n = 8 in <i><i>Kif15</i></i>^<i>+/+</i>group, n = 6 in <i><i>Kif15</i></i>^<i>-/-</i> group (<b>H and K</b>): The expression of PSD95 and GluN2A in hippocampus of <i><i>Kif15</i></i>^<i>-/-</i> mice was lower than that of wild type mice at 6 weeks, n = 6 in <i><i>Kif15</i></i>^<i>+/+</i> group, n = 8 in <i><i>Kif15</i></i>^<i>-/-</i> group. …”

Image 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.jpeg by Xin Fei (20466992)

“…After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”

Immunogenicity results of different vaccination schemes at different time points. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against laboratory-confirmed infections during the different waves. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against acute-care hospitalization attributed to laboratory-confirmed infections during the differen... by Rima Moghnieh (679199)

Subjects:

Immunogenicity assessment groups based on the primary and booster vaccination schemes and timeframe from the second or booster dose. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.4/BA.5 variant wave. by Rima Moghnieh (679199)

Subjects:

Humoral immune responses to SARS-CoV-2 spike protein following various primary vaccination schemes and booster doses with Sinopharm or Pfizer vaccines among COVID-19-naïve particip... by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Alpha variant wave. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.1/BA.2 variant wave. by Rima Moghnieh (679199)

Subjects:

Fig 4 - by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Delta variant wave. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the mixed Delta and Omicron variant wave. by Rima Moghnieh (679199)

Subjects:

COVID-19 in Lebanon: The daily number of COVID-19 cases throughout the waves of the pandemic in Lebanon and associated SARS-CoV-2 variants between January 2021 and September 2022. by Rima Moghnieh (679199)

Subjects:

Study profile. by Rima Moghnieh (679199)

Subjects:

Fig 3 - by Rima Moghnieh (679199)

Subjects:

Multiproxy summary of pollen, fecal biomarker, and charcoal data for BF19. by John A. F. Wendt (19976392)